JPH06501841A - サイトメガウイルス感染の作用を変調するオリゴヌクレオチド - Google Patents
サイトメガウイルス感染の作用を変調するオリゴヌクレオチドInfo
- Publication number
- JPH06501841A JPH06501841A JP3513776A JP51377691A JPH06501841A JP H06501841 A JPH06501841 A JP H06501841A JP 3513776 A JP3513776 A JP 3513776A JP 51377691 A JP51377691 A JP 51377691A JP H06501841 A JPH06501841 A JP H06501841A
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- array
- analogs
- oligonucleotides
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.サイトメガロウイルスのIE1、IE2またはDNAポリメラーゼ遺伝子か ら誘導されるRNAまたはDNAの少なくとも一部分と特異的にハイブリッド形 成しうるオリゴヌクレオチドまたはオリゴヌクレオチド類似体。 2.DNAポリメラーゼ遺伝子のmRNAキャップ部位、AUG領域、保存アミ ノ酸領域または塩基608〜697若しくは1109〜1159間のCMV挿入 領域の少なくとも一部分と特異的にハイブリッド形成しうる請求項1に記載のオ リゴヌクレオチドまたはオリゴヌクレオチド類似体。 3.IE1遺伝子のmRNAキャップ部位、AUG領域またはイントロン/エキ ソン結合領域の少なくとも一部分と特異的にハイブリッド形成しうる請求項1に 記載のオリゴヌクレオチドまたはオリゴヌクレオチド類似体。 4.IE2遺伝子のAUG/CAP部位、AUG領域、IE2特異的イントロン /エキソン結合領域または核部位シグナル領域の少なくとも一部分と特異的にハ イブリッド形成しうる請求項1に記載のオリゴヌクレオチドまたはオリゴヌクレ オチド類似体。 5.薬学的に許容しうる担体中の請求項1に記載のオリゴヌクレオチドまたはオ リゴヌクレオチド類似体。 6.5個〜約50個の核酸塩基単位を有する請求項1に記載のオリゴヌクレオチ ドまたはオリゴヌクレオチド類似体。 7.8個〜約25個の核酸塩基単位を有する請求項1に記載のオリゴヌクレオチ ドまたはオリゴヌクレオチド類似体。 8.12個〜約25個の核酸塩基単位を有する請求項1に記載のオリゴヌクレオ チドまたはオリゴヌクレオチド類似体。 9.オリゴヌクレオチドのヌクレオチド単位間の少なくとも若干の結合性基が硫 黄含有種を含む請求項1に記載のオリゴヌクレオチドまたはオリゴヌクレオチド 類似体。 10.オリゴヌクレオチドのヌクレオチド単位間の少なくとも若干の結合性基が ホスホロチオエート残基を含む請求項1に記載のオリゴヌクレオチドまたはオリ ゴヌクレオチド類似体。 11.配列 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】,または 【配列があります】. の内の一つの少なくとも一部分のDNAまたは対応するRNA若しくは前メッセ ンジャーRNAに対して相補的なオリゴヌクレオチドまたはオリゴヌクレオチド 類似体。 12.薬学的に許容しうる担体中の請求項11に記載のオリゴヌクレオチドまた はオリゴヌクレオチド類似体。 13.オリゴヌクレオチドのヌクレオチド単位間の少なくとも若干の結合性基が 硫黄含有種を含む請求項11に記載のオリゴヌクレオチドまたはオリゴヌクレオ チド類似体。 14.オリゴヌクレオチドのヌクレオチド単位間の少なくとも若干の結合性基が ホスホロチオエート残基を含む請求項11に記載のオリゴヌクレオチドまたはオ リゴヌクレオチド類似体。 15.サイトメガロウイルス感染の活性を変調する方法であって、CMVに感染 していると疑われる動物に、サイトメガロウイルスのIE1、IE2またはDN Aポリメラーゼ遺伝子から誘導されるRNAまたはDNAの少なくとも一部分と 特異的にハイブリッド形成しうるオリゴヌクレオチドまたはオリゴヌクレオチド 類似体を接触させることを含む上記の方法。 16.前記の感染がヒトサイトメガロウイルスによる請求項15に記載の方法。 17.オリゴヌクレオチドまたはオリゴヌクレオチド類似体が、DNAポリメラ ーゼ遺伝子のmRNAキャップ部位、AUG領域、保存アミノ酸領域または塩基 608〜697若しくは1109〜1159間のCMV挿入領域の少なくとも一 部分と特異的にハイブリッド形成しうる請求項15に記載の方法。 18.オリゴヌクレオチドまたはオリゴヌクレオチド類似体が、IE1遺伝子の mRNAキャップ部位、AUG領域またはイントロン/エキソン結合領域の少な くとも一部分と特異的にハイブリッド形成しうる請求項15に記載の方法。 19.オリゴヌクレオチドまたはオリゴヌクレオチド類似体が、IE2遺伝子の AUG/CAP部位、AUG領域、IE2特異的イントロン/エキソン結合領域 または核部位シグナル領域の少なくとも一部分と特異的にハイブリッド形成しう る請求項15に記載の方法。 20.オリゴヌクレオチドまたはオリゴヌクレオチド類似体が薬学的に許容しう る担体中にある請求項15に記載の方法。 21.オリゴヌクレオチドまたはオリゴヌクレオチド類似体が5個〜約50個の 核酸塩基単位を有する請求項15に記載の方法22.オリゴヌクレオチドまたは オリゴヌクレオチド類似体が8個〜約25個の核酸塩基単位を有する請求項15 に記載の方法23.オリゴヌクレオチドまたはオリゴヌクレオチド類似体が12 個〜約25個の核酸塩基単位を有する請求項15に記載の方法24.オリゴヌク レオチドのヌクレオチド単位間の少なくとも若干の結合性基が硫黄含有種を含む 請求項15に記載の方法。 25.オリゴヌクレオチドのヌクレオチド単位間の少なくとも若干の結合性基が ホスホロチオエート残基を含む請求項15記載の方法。 26.サイトメガロウイルス感染の活性を変調する方法であって、CMVに感染 していると疑われる動物に、配列 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】,【配列があります】,【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】, 【配列があります】,または 【配列があります】. の内の一つの少なくとも一部分のDNAまたは対応するRNA若しくは前メッセ ンジャーRNAに対して相補的なオリゴヌクレオチドまたはオリゴヌクレオチド 類似体を接触させることを含む上記の方法。 27.表2に定義された配列の一つの少くとも一部分を含むサイトメガロウイル スのDNAまたは対応するmRNA若しくは前mRNAと特異的にハイブリッド 形成しうるオリゴヌクレオチドまたはオリゴヌクレオチド類似体。 28.薬学的に許容しうる担体中の請求項27に記載のオリゴヌクレオチドまた はオリゴヌクレオチド類似体。 29.オリゴヌクレオチドのヌクレオチド単位間の少なくとも若干の結合性基が 硫黄含有種を含む請求項27に記載のオリゴヌクレオチドまたはオリゴヌクレオ チド類似体。 30.オリゴヌクレオチドのヌクレオチド単位間の少なくとも若干の結合性基か ホスホロチオエート残基を含む請求項27に記載のオリゴヌクレオチドまたはオ リゴヌクレオチド類似体。 31.少なくとも若干のヌクレオチド塩基か2′−O−アルキル修飾を有する請 求項27に記載のオリゴヌクレオチドまたはオリゴヌクレオチド類似体。 32.修飾された塩基か2′−O−メチルである請求項31に記載のオリゴヌク レオチドまたはオリゴヌクレオチド類似体。 33.サイトメガロウイルス感染の活性を変調する方法であって、サイトメガロ ウイルスに感染していると疑われる動物に、表2に定義された配列の内の一つの 少なくとも一部分を含むサイトメガロウイルスのDNAまたは対応するmRNA 若しくは前mRNAと特異的にハイブリッド形成しうるオリゴヌクレオチドまた はオリゴヌクレオチド類似体の治療的有効量を接触させることを含む上記の方法 。 34.オリゴヌクレオチドまたはオリゴヌクレオチド類似体が薬学的に許容しう る担体中にある請求項33に記載の方法。 35.オリゴヌクレオチドのヌクレオチド単位間の少なくとも若干の結合性基が 硫黄含有種を含む請求項33に記載の方法。 36.オリゴヌクレオチドのヌクレオチド単位間の少なくとも若干の結合性基が ホスホロチオエート残基を含む請求項33に記載の方法。 37.オリゴヌクレオチドの少なくとも若干のヌクレオチド塩基が2′−O−ア ルキル修飾を有する請求項33に記載の方法。 38.修飾された塩基が2′−O−メチルである請求項37に記載の方法。 39.ホスホロチオエート結合を有する2′−O−メチル修飾ヌクレオシドを含 む請求項27に記載のオリゴヌクレオチドまたはオリゴヌクレオチド類似体。 40.前記のオリゴヌクレオチドが、ホスホロチオエート結合を有する2′−O −メチル修飾ヌクレオシドを含む請求項33に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56836690A | 1990-08-16 | 1990-08-16 | |
US568,366 | 1990-08-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06501841A true JPH06501841A (ja) | 1994-03-03 |
JP2708960B2 JP2708960B2 (ja) | 1998-02-04 |
Family
ID=24270996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3513776A Expired - Lifetime JP2708960B2 (ja) | 1990-08-16 | 1991-08-14 | サイトメガウイルス感染の作用を変調するオリゴヌクレオチド |
Country Status (16)
Country | Link |
---|---|
US (1) | US5591720A (ja) |
EP (1) | EP0544713B1 (ja) |
JP (1) | JP2708960B2 (ja) |
KR (1) | KR970005273B1 (ja) |
AT (1) | ATE154947T1 (ja) |
AU (1) | AU649717B2 (ja) |
BR (2) | BR9106751A (ja) |
CA (1) | CA2089666C (ja) |
DE (1) | DE69126710T2 (ja) |
DK (1) | DK0544713T3 (ja) |
ES (1) | ES2104717T3 (ja) |
FI (1) | FI930658A0 (ja) |
GR (1) | GR3024873T3 (ja) |
HU (1) | HUT63430A (ja) |
NO (1) | NO930515L (ja) |
WO (1) | WO1992003456A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019502371A (ja) * | 2015-11-20 | 2019-01-31 | オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ | マイクロrna認識エレメントを含むcmvベクター |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
US5789573A (en) * | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
US5595978A (en) * | 1990-08-16 | 1997-01-21 | Isis Pharmaceuticals, Inc. | Composition and method for treatment of CMV retinites |
US6153595A (en) * | 1990-08-16 | 2000-11-28 | Isis Pharmaceuticals Inc. | Composition and method for treatment of CMV infections |
US7119184B2 (en) | 1991-08-12 | 2006-10-10 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
US6369209B1 (en) | 1999-05-03 | 2002-04-09 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
US6824976B1 (en) | 1993-04-02 | 2004-11-30 | Rigel Pharmaceuticals, Inc. | Method for selective inactivation of viral replication |
WO1994023041A2 (en) * | 1993-04-02 | 1994-10-13 | Ribogene, Inc. | Method for selective inactivation of viral replication |
US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5801235A (en) * | 1994-05-25 | 1998-09-01 | Hybridon, Inc. | Oligonucleotides with anti-cytomegalovirus activity |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
ES2267100T5 (es) | 1994-07-15 | 2011-04-08 | The University Of Iowa Research Foundation | Oligonucleótidos inmunomoduladores. |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
AU2215097A (en) * | 1996-03-14 | 1997-10-01 | Hybridon, Inc. | Selected oligonucleotides with anti-cytomegalovirus activity |
AU3309697A (en) * | 1996-06-18 | 1998-01-07 | Hybridon, Inc. | Compositions and methods for treating specific gene expression-related diseases and disorders in humans |
EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
US6576752B1 (en) | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
US6127533A (en) * | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
CA2281838A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
WO1998046740A1 (en) * | 1997-04-17 | 1998-10-22 | Antivirals, Inc. | Method of treating restenosis by antisense targeting of cmv |
US6339068B1 (en) | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
US20070149472A1 (en) * | 1997-08-13 | 2007-06-28 | Mckay Robert | Antisense oligonucleotide compositions and methods for the modulation of jnk proteins |
US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
CA2323929C (en) | 1998-04-03 | 2004-03-09 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
WO1999060167A1 (en) * | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for topical delivery of oligonucleotides |
US6867294B1 (en) * | 1998-07-14 | 2005-03-15 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
US6277967B1 (en) | 1998-07-14 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
US6242589B1 (en) | 1998-07-14 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides having modified internucleoside linkages |
US6335194B1 (en) | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
ID30093A (id) | 1999-02-12 | 2001-11-01 | Sankyo Co | Analog-analog nukleosida dan oligonukleotida baru |
JP4151751B2 (ja) * | 1999-07-22 | 2008-09-17 | 第一三共株式会社 | 新規ビシクロヌクレオシド類縁体 |
US6147200A (en) * | 1999-08-19 | 2000-11-14 | Isis Pharmaceuticals, Inc. | 2'-O-acetamido modified monomers and oligomers |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
IL160157A0 (en) | 2001-08-17 | 2004-07-25 | Coley Pharm Group Inc | Combination motif immune stimulation oligonucleotides with improved activity |
KR20040008342A (ko) * | 2002-07-18 | 2004-01-31 | 한국전력공사 | 산업용 보일러의 화학세정시 발생하는 폐액 재활용 방법 |
KR101360955B1 (ko) * | 2002-09-13 | 2014-02-10 | 레플리코르 인코포레이티드 | 비서열 상보적 항바이러스 올리고뉴클레오티드 |
US20050196382A1 (en) * | 2002-09-13 | 2005-09-08 | Replicor, Inc. | Antiviral oligonucleotides targeting viral families |
BR0315810A (pt) | 2002-10-29 | 2005-09-13 | Coley Pharmaceutical Group Ltd | Uso de oligonucleotìdeos cpg no tratamento de infecção por vìrus da hepatite c |
WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
CN103717735A (zh) | 2011-07-22 | 2014-04-09 | 公立大学法人横滨市立大学 | 切断mRNA的多聚(A)链和/或3’末端序列的一部分而抑制翻译反应的技术 |
SG11201705312PA (en) | 2014-12-29 | 2017-07-28 | Bonac Corp | Composition containing nucleic acid molecule stably |
US20210395746A1 (en) * | 2018-06-12 | 2021-12-23 | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads | Compositions for herpesvirus transcriptional feedback circuit disruption and uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5248670A (en) * | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
-
1991
- 1991-08-14 JP JP3513776A patent/JP2708960B2/ja not_active Expired - Lifetime
- 1991-08-14 DE DE69126710T patent/DE69126710T2/de not_active Expired - Fee Related
- 1991-08-14 DK DK91914366.9T patent/DK0544713T3/da active
- 1991-08-14 US US07/927,506 patent/US5591720A/en not_active Expired - Lifetime
- 1991-08-14 AT AT91914366T patent/ATE154947T1/de not_active IP Right Cessation
- 1991-08-14 AU AU84393/91A patent/AU649717B2/en not_active Ceased
- 1991-08-14 EP EP91914366A patent/EP0544713B1/en not_active Expired - Lifetime
- 1991-08-14 HU HU93398A patent/HUT63430A/hu unknown
- 1991-08-14 ES ES91914366T patent/ES2104717T3/es not_active Expired - Lifetime
- 1991-08-14 KR KR1019930700439A patent/KR970005273B1/ko not_active IP Right Cessation
- 1991-08-14 WO PCT/US1991/005815 patent/WO1992003456A1/en active IP Right Grant
- 1991-08-14 CA CA002089666A patent/CA2089666C/en not_active Expired - Lifetime
- 1991-08-14 BR BR919106751A patent/BR9106751A/pt not_active Application Discontinuation
-
1993
- 1993-02-12 NO NO93930515A patent/NO930515L/no unknown
- 1993-02-15 FI FI930658A patent/FI930658A0/fi not_active Application Discontinuation
-
1997
- 1997-05-14 BR BR1100909-8A patent/BR1100909A/pt active IP Right Grant
- 1997-09-26 GR GR970402519T patent/GR3024873T3/el unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019502371A (ja) * | 2015-11-20 | 2019-01-31 | オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ | マイクロrna認識エレメントを含むcmvベクター |
Also Published As
Publication number | Publication date |
---|---|
CA2089666A1 (en) | 1992-02-17 |
EP0544713A1 (en) | 1993-06-09 |
EP0544713B1 (en) | 1997-07-02 |
CA2089666C (en) | 2003-01-07 |
ATE154947T1 (de) | 1997-07-15 |
BR1100909A (pt) | 2000-06-06 |
DE69126710T2 (de) | 1998-01-15 |
AU649717B2 (en) | 1994-06-02 |
HU9300398D0 (en) | 1993-05-28 |
NO930515L (no) | 1993-03-31 |
NO930515D0 (no) | 1993-02-12 |
JP2708960B2 (ja) | 1998-02-04 |
AU8439391A (en) | 1992-03-17 |
KR970005273B1 (ko) | 1997-04-15 |
ES2104717T3 (es) | 1997-10-16 |
GR3024873T3 (en) | 1998-01-30 |
BR9106751A (pt) | 1993-08-17 |
DK0544713T3 (da) | 1997-09-29 |
FI930658A (fi) | 1993-02-15 |
US5591720A (en) | 1997-01-07 |
EP0544713A4 (en) | 1994-05-18 |
KR930701465A (ko) | 1993-06-11 |
FI930658A0 (fi) | 1993-02-15 |
WO1992003456A1 (en) | 1992-03-05 |
HUT63430A (en) | 1993-08-30 |
DE69126710D1 (de) | 1997-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06501841A (ja) | サイトメガウイルス感染の作用を変調するオリゴヌクレオチド | |
EP0714436B1 (en) | Oligonucleotides with activity against human immunodeficiency virus | |
JP2798305B2 (ja) | アンチセンスオリゴヌクレオチドおよびヒト免疫不全ウイルス感染におけるその使用 | |
US5442049A (en) | Oligonucleotides for modulating the effects of cytomegalovirus infections | |
US20040209263A1 (en) | Selection of catalytic nucleic acids targeted to infectious agents | |
US20040248296A1 (en) | HIV therapeutic | |
US5739309A (en) | Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens | |
JPH08504570A (ja) | 治療用抗hivオリゴヌクレオチドと薬剤 | |
US20150005365A1 (en) | Methods for diagnosing and treating learning or mental disorders | |
JP3307944B2 (ja) | ヒト・免疫不全ウイルスの増殖阻害化合物および方法 | |
JPH09500787A (ja) | 蛋白生産、細胞増殖および/または感染症病原体の増殖に対するオリゴヌクレオチド阻害の促進 | |
US20060128617A1 (en) | Oligoribonucleotide or peptidic nucleic acid inhibiting function of hepatitis c virus | |
US5550047A (en) | Oligonucleotides with anti-Epstein-Barr virus activity | |
CA2211877A1 (en) | Human immunodeficiency virus transcription inhibitors and methods of their use | |
AU2002228756B2 (en) | Selection of catalytic nucleic acids targeted to infectious agents | |
US6828148B2 (en) | Miniribozymes active at low magnesium ion concentrations | |
JP2004283024A (ja) | 新規アンチセンスオリゴヌクレオチド及び抗hiv剤 | |
WO2011046221A1 (ja) | インターフェロン-αモジュレーター | |
AU2002228756A1 (en) | Selection of catalytic nucleic acids targeted to infectious agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081017 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081017 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091017 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101017 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101017 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111017 Year of fee payment: 14 |
|
EXPY | Cancellation because of completion of term |